FME.DE · Intrinsic value
Is Fresenius Medical Care AG (FME.DE) overvalued or undervalued?
As of Oct 19, 2026, TickerWorth's valuation lenses put Fresenius Medical Care AG (FME.DE) at €32.18 – €112.59, too broad a range to say where the delayed market price of €39.04 sits in it, so we do not call it over- or undervalued. It is a model estimate, and every input behind it is sourced below.
Model by Miraaj Patel · generated from market data · Updated Oct 19, 2026 · How these pages are made
What is FME.DE worth?
- Fair-value range
- €32.18 – €112.59
- Market price
- €39.04
- Gap to fair value
- —
- Verdict
- Too wide to call
Reverse DCF: Today's price implies revenue growth of −9.5% a year for 5 years; our model assumes 2.7% a year on average over the same horizon.
What is FME.DE's TickerWorth Score?
Middle of the pack — real strengths and real weaknesses
Compared with Healthcare companies in Europe
Its strongest point: looks cheap on the numbers. Its weakest: profitability is weak.
- Value · 98 of 100
Cheaper than 98% of Healthcare companies in Europe
- Price vs worth · 100 of 100
- Quality · 21 of 100
More profitable than 21% of Healthcare companies in Europe
- Financial health · 21 of 100
Financially stronger than 21% of Healthcare companies in Europe
- Growth · 25 of 100
Growing faster than 25% of Healthcare companies in Europe
- Momentum · 30 of 100
Outperformed 30% of Healthcare companies in Europe over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
Why FME.DE gets a range, not one number
At a recent price of €39.04, Fresenius Medical Care AG (FME.DE) sits inside a range too wide to call either way: our valuation lenses put the business somewhere between €32.18 and €112.59 per share. They disagree too widely for us to state a single fair value. We publish the range rather than a midpoint because a number that precise would claim more than the methods can support. This is an educational model, not a price target or a recommendation.
Read the full reasoning
The valuation discounts Fresenius Medical Care AG's projected free cash flows at a weighted-average cost of capital (WACC) of 7.2%, with a long-run terminal growth rate of 2.5%. About 80% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — the market is implying roughly -9.5% annual revenue growth for FME.DE. Our base case instead compounds to about 2.7% a year over the same forecast, so the market is pricing in slower growth than our base case. The reverse-DCF is a quick sanity check: it reframes 'is this stock cheap?' as 'do I believe the growth the price requires?' rather than arguing over a single point estimate of fair value.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, FME.DE's modeled DCF value ranges from about €53.50 to €235.94 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what Fresenius Medical Care AG would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of FME.DE's intrinsic value. Figures update as new filings and prices come in.
Every input behind FME.DE's DCF
| Input | Value |
|---|---|
| Base-year revenueLive feed — totalRevenue (TTM) | €19,427,150,000 |
| Base EBIT marginComputed — trailing operatingMargins, held roughly flat | 10.8% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 1% → 2% → 3% → 3% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.1% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 0.81 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesLive feed — sharesOutstanding | 269M |
| Market priceLast known price · as of 2026-10-19 19:33 UTC | €39.04 |
Change FME.DE's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does Fresenius Medical Care AG do?
What does it do?
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It operates in the Medical Care Facilities industry (Healthcare sector), headquartered in Germany. The company employs roughly 107,226 people.
How does it make money?
The business turns 19.4B in annual revenue into profit. Out of every $100 of sales, about $11 is left as operating profit (operating margin of 10.8%), after a 26% gross margin on the products/services it sells. After all costs, taxes and interest, 4.8% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: carries modest debt (0.8× equity), can just cover its short-term bills (1.1× current ratio), and is currently profitable.
FME.DE insider trading
Insider filings are available for US-listed companies only.
Common questions
What is FME.DE's intrinsic value?
TickerWorth's valuation lenses put Fresenius Medical Care AG (FME.DE) between €32.18 and €112.59 per share, versus a market price of €39.04. They disagree too widely for us to state a single fair value, so we publish the range.
Is FME.DE overvalued or undervalued?
At €39.04 the price sits inside a range too wide to call either way. We don't call FME.DE overvalued or undervalued from a range this wide. This is an educational estimate, not advice.
What discount rate is used for FME.DE?
A WACC of 7.2% and a terminal growth rate of 2.5%.
Is Fresenius Medical Care stock undervalued?
TickerWorth's fair-value range for Fresenius Medical Care AG (FME.DE) is €32.18 – €112.59 against a market price of €39.04. Too wide to call. We publish a range here, not one number, so we do not call it over- or undervalued. This is a model estimate, not investment advice.
Fresenius Medical Care (FME.DE) DCF valuation and fair value
Our fair-value range for Fresenius Medical Care AG (FME.DE) is €32.18 – €112.59, built on a 7.2% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into Fresenius Medical Care stock?
Today's price implies revenue growth of −9.5% a year for 5 years; our model assumes 2.7% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of €39.04. A model estimate, not investment advice.
Fresenius Medical Care (FME.DE) insider trading
We have no recent SEC Form 4 insider filings on file for Fresenius Medical Care AG (FME.DE). Form 4 covers US-listed companies only.
Other ways into the coverage
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.